COMPUGEN LTD
No SEC Form 4 filings for $CGEN in the last 30 days.
See all $CGEN insider activity →Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.
Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.
Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CGEN (COMPUGEN LTD). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent CGEN coverage spans financial news and earnings.
The print confirms continued losses despite a sharp revenue rebound, shaping near-term valuation and cash-burn expectations.
Near-term trading focus is the Q1 2027 COM701 interim PFS readout timeline plus cash runway into 2029, which can affect risk appetite and financing expectations.
The article provides the upcoming earnings release timing and consensus EPS/revenue, setting expectations for a near-term volatility window.
Compugen Ltd is expected to report a loss of 7 cents per share, indicating potential short-term weakness in the stock. The bearish sentiment (-0.44 score) aligns with the earnings outlook, suggesting cautious trading stance.
Compugen's upcoming presentation and positive financial updates suggest potential positive sentiment and stock appreciation in the near term.
alphai scores every news story that mentions CGEN with an AI model for sentiment and relevance, and aggregates insider trades from COMPUGEN LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.
2 min readCompugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.
7 min readCompugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.
1 min readCompugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.
3 min readCompugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45–9:25 AM ET. A live webcast and replay will be available on the company’s investor relations website. This follows several positive corporate updates, including strong 2025 financial results, an extended cash runway, and a royalty monetization deal with AstraZeneca.
3 min readCompugen has secured non-dilutive funding from AstraZeneca for rilvegostomig royalties, bolstering its financial stability and extending its cash runway into 2029. The company, rated a 'Buy,' is advancing its pipeline with key catalysts including the phase 3 MAIA-Ovarian cancer trial for COM701 and the phase 1 anti-IL18BP antibody GS-0321. Potential milestone payments of up to $1 billion from AstraZeneca and Gilead, along with mid-single-digit royalties, offer significant future upside.
3 min readCompugen Ltd. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. Management will hold fireside chats and 1x1 meetings at both virtual and in-person events. Live webcasts of the fireside chats will be available on Compugen's investor relations website, with replays accessible afterward.
3 min readRICHMOND HILL, ON, Oct. 27, 2025 /CNW/ -- Compugen Inc., the largest Canadian-owned Technology Ally, is excited to announce the successful award of all technology categories under the Supply Ontario End-User Computing Devices and Services Vendor of Record ( VOR ) Arrangement ( Tender #20172 ) .
2 min readCompugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4 min read
